Tekmira and Pfizer agree research collaboration

Published: 17-Mar-2010
Research & Development Pharmaceutical

They will evaluate SNALP technology to deliver small interfering RNA (siRNA) molecules


Canadian biopharmaceutical firm Tekmira Pharmaceuticals, a developer of RNA interference (RNAi) therapeutics, has signed a research collaboration with Pfizer.

The two companies will collaborate on evaluating Tekmira’s stable nucleic acid-lipid particle (SNALP) technology to deliver small interfering RNA (siRNA) molecules provided by Pfizer. Tekmira will prepare the SNALP formulations and Pfizer will evaluate them in preclinical models. Financial terms were not disclosed.

Mark Murray, Tekmira's chief executive, said: ‘The collaboration combines Tekmira's expertise in the delivery of RNAi therapeutics with Pfizer's research excellence in nucleic acid therapeutics.’

Tekmira aims to sign additional collaborative agreements in 2010. The firm currently has licence or collaborative agreements in place with seven other pharmaceutical and biotechnology companies.

  • Companies:
  • Pfizer
  • Tekmira Pharmaceuticals
See more

You may also like

Manufacturing

Samsung Biologics and Pfizer's collaboration for manufacturing of biosimilars

Read more
Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio

Trending Articles

  1. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  2. Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  5. Amarna Therapeutics appoints Aurelia Caparrós as new Chief Business Officer Aurellia will be reponsible for driving Amarna's growth in the Netherlands and Spain

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Samsung Biologics and Pfizer's collaboration for manufacturing of biosimilars

Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Drug Delivery

Pfizer enters into merger with Seagen

The companies expect to complete the transaction in late 2023 or early 2024, subject to fulfilment of customary closing conditions
Manufacturing

Tickets now on sale for 2023 Manufacturing Chemist Live

Super early bird tickets are now on sale for the annual conference due to take place in Birmingham on 24 – 25 May 2023
Research & Development

Touchlight and Pfizer to use dbDNA to manufacture mRNA-based vaccines, therapeutics and gene therapies

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies
Research & Development

Pfizer joins drug target identification consortium

Open Targets works pre-competitively, aiming to bridge the gap between pharma companies and not-for-profit research bodies
Ingredients

Therapeutic: abrocitinib for atopic dermatitis

Atopic dermatitis (AD) is a chronic skin condition; patients experience inflammation of the skin and defects in the skin barrier
Research & Development

Alternating vaccines trial expands to include two additional vaccines

Volunteers, who will have received either the Oxford-AstraZeneca, or Pfizer vaccine, will be randomly allocated to receive either the same vaccine for their second dose, or a dose of the COVID-19 vaccines produced by Moderna or Novavax
Subscribe now